Clinical Scorecard: Association of Age and Ocular Surface Parameters with Morphological Alterations in Meibomian Glands
At a Glance
Category
Detail
Condition
Meibomian Gland Dysfunction (MGD) and dry eye disease
Key Mechanisms
Terminal duct obstruction and/or qualitative or quantitative changes in meibomian gland secretions leading to tear film instability and evaporative dry eye
Target Population
Patients presenting to ophthalmology clinics, adults and children excluding those with systemic diseases or ocular conditions affecting MGs
Care Setting
Ophthalmology outpatient clinics with access to slit-lamp biomicroscopy and infrared meibography
Key Highlights
MGD accounts for 50–70% of dry eye disease and causes tear film instability and evaporative dry eye.
Infrared meibography is a noninvasive, rapid, and low-cost method for direct visualization of meibomian gland morphology.
Objective assessment of MG morphology correlates with demographic characteristics and dry eye parameters, aiding diagnosis and treatment.
Guideline-Based Recommendations
Diagnosis
Use slit-lamp biomicroscopy and infrared meibography to assess meibomian gland morphology and gland loss.
Evaluate tear film stability with tear breakup time (TBUT) and basal tear secretion with Schirmer I test.
Assess patient symptoms using the Ocular Surface Disease Index (OSDI) questionnaire.
Management
Identify and exclude systemic diseases, eyelid disorders, contact lens use, and medications that may affect MG function.
Employ noninvasive imaging techniques like infrared meibography for monitoring MG morphology during treatment.
Monitoring & Follow-up
Regularly assess MG morphology and function using meibography and clinical tests (TBUT, Schirmer I).
Monitor symptom severity and impact on quality of life using OSDI scores.
Risks
MGD can lead to ocular surface damage, contact lens intolerance, and giant papillary conjunctivitis if untreated.
Patient discomfort and time consumption limit some traditional MG assessment techniques.
Patient & Prescribing Data
155 eyes from 155 patients aged variably, excluding those with systemic or ocular conditions affecting MGs
Objective imaging and symptom assessment guide diagnosis and individualized management of dry eye related to MGD
Clinical Best Practices
Obtain informed consent and exclude confounding systemic and ocular conditions before assessment.
Use standardized protocols for TBUT and Schirmer I tests to ensure reliable tear film evaluation.
Perform infrared meibography with patient cooperation for accurate MG morphology imaging.
Utilize validated symptom questionnaires like OSDI to quantify patient-reported dry eye severity.
Interpret meibography findings in conjunction with clinical signs and symptoms for comprehensive evaluation.
